Pulmonary Hypertension trial results

Met endpoint

Mosliciguat

Phase 2 n=135 Pulmonary Hypertension

Roivant ROIV

24h stock move +18.75%
Missed endpoint

TNX-103

Phase 3 n=230 Pulmonary Hypertension

Tenax Therapeutics TENX

24h stock move −89.29%